Evidence map›Paper›PMID 27943278›Full record

ArticleInternational journal of cancer2017

Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas.

Bradley M Haverkos, Ying Huang, Alejandro Gru, Preeti Pancholi, Aharon G Freud, Anjali Mishra, Amy S Ruppert, Robert A Baiocchi, Pierluigi Porcu

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03964480 (Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03964480 recruitingnot on this mapstarted 2018, after this paper: background citation

Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

Typeobservational_patient_registrySponsorAssociazione Angela Serra per la ricerca sul cancroRan2018 to 2025Enrolled1,000ConditionsPeripheral T-Cell Lymphoma
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Bradley M HaverkosDivision of Hematology, University of Colorado, Aurora, CO.
Ying HuangDivision of Hematology, The Ohio State University, Columbus, OH.
Alejandro GruDepartment of Pathology, University of Virginia, Charlottesville, VA.
Preeti PancholiDepartment of Pathology, The Ohio State University, Columbus, OH.
Aharon G FreudDepartment of Pathology, The Ohio State University, Columbus, OH.
Anjali MishraComprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH.
Amy S RuppertDivision of Hematology, The Ohio State University, Columbus, OH.
Robert A BaiocchiDivision of Hematology, The Ohio State University, Columbus, OH.
Pierluigi PorcuDivision of Hematology, The Ohio State University, Columbus, OH.
The Ohio State University · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USUniversity of Colorado Denver · USUniversity of Virginia · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Training Hematology and Oncology Fellows in Clinical ResearchT32CA165998 · NCI · OHIO STATE UNIVERSITY · PI CLINTON, STEVEN K, GARZON, RAMIRO · 2012 to 2016
$944k
NCI NIH HHS L30 CA189070NCI NIH HHS P30 CA016058NCI NIH HHS T32 CA165998
6 · The paper itself

Abstract

Epstein-Barr virus (EBV)-encoded RNAs (EBER) in tumor tissue and cell-free plasma EBV-DNA (pEBVd) are detected in EBV-associated lymphomas. Studies have suggested that EBER+ peripheral T-cell lymphomas (PTCL) have worse prognosis but the role of EBV in these neoplasms remains unclear. pEBVd is quantitative and more easily amenable to standardization than EBER, but frequency of pEBVd detection, clinical impact and agreement with EBER status in PTCL are unknown. We retrospectively assessed frequency of detectable pre-treatment pEBVd, presence of EBER in tumor tissue, and outcomes in 61 of 135 EBV-assessable PTCL patients. Fifteen of 61 patients (24.5%, 95% CI: 14-37%) were pre-treatment pEBVd+, with no significant differences in baseline characteristics or treatment between pEBVd+ and pEBVd- patients. EBER-ISH was performed on 10 pEBVd+ and 35 pEBVd- tumors. All 10 pEBVd+ patients were EBER+, but 9 pEBVd- patients were also EBER+. With median follow up of 24 months (range 1-96), overall survival (OS) was shorter in pEBVd+ compared to pEBVd- patients (13 vs. 72 months; p = 0.04). In our retrospective study, pre-treatment pEBVd was elevated in 25% of PTCL patients, was highly specific for EBER+ tumors, and was associated with shorter survival. pEBVd should be further explored as a prognostic variable and tumor biomarker in PTCL.

Indexed as

PrognosisAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalDNA, ViralFemaleHerpesvirus 4, HumanHumansIn Situ HybridizationLymphoma, T-Cell, PeripheralMaleMiddle AgedBiomarkers, TumorDNA, Viralcell-free DNAEBVEpstein-Barr virusperipheral T-cell lymphomaPTCL

Identifiers

PMID27943278
PMCPMC5323329
OpenAlexW2560808900

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.